| Zacks Company Profile for ProPhase Labs, Inc. (PRPH : NSDQ) |
|
|
| |
| • Company Description |
| ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZE?, a zinc gluconate glycine product. COLD-EEZE? family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania.
Number of Employees: 96 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.43 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 4,106,065 shares |
| Shares Outstanding: 41.54 (millions) |
| Market Capitalization: $17.85 (millions) |
| Beta: -0.41 |
| 52 Week High: $3.55 |
| 52 Week Low: $0.22 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
26.41% |
21.68% |
| 12 Week |
49.18% |
25.48% |
| Year To Date |
-43.23% |
-46.84% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Ted Karkus - Chief Executive Officer and Chairman
Louis Gleckel - Director
Warren Hirsch - Director
Louis Gleckel - Director
Warren Hirsch - Director
|
|
Peer Information
ProPhase Labs, Inc. (GSAC)
ProPhase Labs, Inc. (CASI)
ProPhase Labs, Inc. (ALCD.)
ProPhase Labs, Inc. (OMNN)
ProPhase Labs, Inc. (CGPI.)
ProPhase Labs, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 74345W108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
|
|
Share - Related Items
Shares Outstanding: 41.54
Most Recent Split Date: 1.00 (2.00:1)
Beta: -0.41
Market Capitalization: $17.85 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.11 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.56 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/13/25 |
|
|
|
| |
